Get the Stockscreener App
2.03
0.98%
-0.02
Autolus Therapeutics Plc Adr stock is traded at $2.03, with a volume of 2.70M.
It is down -0.98% in the last 24 hours and up +52.63% over the past month.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
See More
Previous Close:
$2.05
Open:
$2.03
24h Volume:
2.70M
Relative Volume:
1.21
Market Cap:
$620.10M
Revenue:
-
Net Income/Loss:
$-208.38M
P/E Ratio:
-1.6917
EPS:
-1.2
Net Cash Flow:
$-156.57M
1W Performance:
-12.88%
1M Performance:
+52.63%
6M Performance:
-18.47%
1Y Performance:
-52.90%
1-Day Range:
$2.00
$2.07
1-Week Range:
$2.00
$2.37
52-Week Range:
$1.105
$5.00
Autolus Therapeutics Plc Adr Stock (AUTL) Company Profile
Name
Autolus Therapeutics Plc Adr
Sector
Industry
Phone
44 20 3829 6230
Address
THE MEDIAWORKS, LONDON
Compare AUTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUTL
Autolus Therapeutics Plc Adr
|
2.03 | 620.10M | 0 | -208.38M | -156.57M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Autolus Therapeutics Plc Adr Stock (AUTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Upgrade | Goldman | Neutral → Buy |
| Nov-15-24 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Mar-27-23 | Resumed | Wells Fargo | Overweight |
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| Jun-14-21 | Upgrade | Jefferies | Hold → Buy |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | JP Morgan | Overweight |
| Jul-22-20 | Initiated | SunTrust | Buy |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Sep-23-19 | Initiated | Needham | Buy |
| May-17-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-24-18 | Initiated | H.C. Wainwright | Buy |
View All
Autolus Therapeutics Plc Adr Stock (AUTL) Latest News
Closing Figures: Autolus Therapeutics plc ADR (AUTL)’s Negative Finish at 2.05, Down -3.30 - DWinneX
NOV Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - investchronicle.com
Autolus shares surge 77% following InvestingPro’s April Fair Value signal By Investing.com - Investing.com India
EMA committee endorses Autolus’ leukemia therapy obe-cel By Investing.com - Investing.com South Africa
Autolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment Brightens By Stocktwits - Investing.com India
EMA committee endorses Autolus’ leukemia therapy obe-cel - Investing.com
Autolus Therapeutics plc ADR (AUTL) Has A Gold Mine On Its Hands - Stocksregister
Autolus reports $9M in Q1 product revenue, gains UK approval By Investing.com - Investing.com South Africa
Autolus reports $9M in Q1 product revenue, gains UK approval - Investing.com
AUTL’s Market Whiplash: -44.26% YTD Decline, -21.08% Plunge in 30 Days - investchronicle.com
There is no doubt that Autolus Therapeutics plc ADR (AUTL) ticks all the boxes. - Sete News
Autolus Therapeutics plc ADR (AUTL) receives a Buy rating from Goldman - knoxdaily.com
AUTL’s valuation metrics: A comprehensive analysis - uspostnews.com
Market Resilience: Autolus Therapeutics plc ADR (AUTL) Finishes Weak at 1.33, Down -5.00 - DWinneX
Market Update: Goosehead Insurance Inc (GSHD) Sees Positive Movement, Closing at 99.54 - DWinneX
How Do Things Look For Autolus Therapeutics plc ADR (NASDAQ: AUTL) In The Short-Term? - Stocksregister
UK approves Autolus leukemia therapy with conditions By Investing.com - Investing.com India
For Autolus Therapeutics plc ADR [AUTL], Analyst sees a rise to $7.60. What next? - dbtnews.com
UK approves Autolus leukemia therapy with conditions - Investing.com
Autolus Therapeutics plc ADR [NASDAQ: AUTL] Sees Decrease in Stock Value - knoxdaily.com
Market cap of i-80 Gold Corp [IAUX] reaches 279.54M – now what? - dbtnews.com
Daiwa Securities lifts Bilibili Inc ADR [BILI] price estimate. Who else is bullish? - dbtnews.com
Market Watch: Autolus Therapeutics plc ADR (AUTL)’s Noteworthy Gain, Closing at 1.60 - DWinneX
It makes sense and dollars to buy Autolus Therapeutics plc ADR (AUTL) stock - Sete News
How does PROG Holdings Inc (PRG) change from a tortoise to a hare? - Sete News
Investors in cash trouble should check out BBB Foods Inc (TBBB) - Sete News
Take off with Energous Corp (WATT): Get ready for trading - Sete News
The growth track for Protalix BioTherapeutics Inc (PLX) has changed recently - Sete News
Tokio Marine Holdings, Inc. Sponsored ADR (OTCMKTS:TKOMY) Short Interest Update - Defense World
Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - GlobeNewswire Inc.
PSQ Holdings Inc (PSQH) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Truist cuts Autolus stock price target to $10, maintains buy rating By Investing.com - Investing.com South Africa
Truist cuts Autolus stock price target to $10, maintains buy rating - Investing.com India
Agilent tech aids in FDA approval of Autolus CAR T therapy By Investing.com - Investing.com South Africa
Arhaus Inc (NASDAQ: ARHS)’s Stock Adds 0.70%, Making It A Good Investment - Stocks Register
Agilent tech aids in FDA approval of Autolus CAR T therapy - Investing.com UK
Truist maintains $11 target on Autolus stock amid strong demand By Investing.com - Investing.com South Africa
Mizuho maintains $12 target on Autolus stock after Q4 update - Investing.com India
Autolus reports progress in commercial launch and financials By Investing.com - Investing.com South Africa
Truist maintains $11 target on Autolus stock amid strong demand - Investing.com India
Autolus reports progress in commercial launch and financials - Investing.com India
Earnings call transcript: Autolus Therapeutics Q4 2024 earnings and market reaction By Investing.com - Investing.com South Africa
Autolus at Leerink’s Global Healthcare Conference: Strategic Moves in CAR T Therapy - Investing.com
10 Best UK Growth Stocks to Buy Now - Insider Monkey
Stock Surge: Autolus Therapeutics plc ADR (AUTL) Closes at 1.82, Marking a 1.68 Increase/Decrease - The Dwinnex
It would be worthwhile to take a closer look at Autolus Therapeutics plc ADR (AUTL) - US Post News
Perhaps timely catching Autolus Therapeutics plc ADR (AUTL) would be a good idea - SETE News
Autolus Therapeutics plc ADR (AUTL) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Autolus Therapeutics plc ADR [AUTL] Officer makes an insider purchase of 698,741 shares worth 2.96 million. - Knox Daily
Lowe’s Cos., Inc Inc. (LOW) Price Performance: The Role of Supply and Demand - The InvestChronicle
Avinger Inc [AVGR] Records 50-Day SMA of $0.7054 - Knox Daily
Autolus Therapeutics Plc Adr Stock (AUTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):